B. Riley lowered the firm’s price target on PDS Biotechnology to $9 from $11 and keeps a Buy rating on the shares. The analyst updated the company’s model post the Q1 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PDSB:
- PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer
- PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
- PDS Biotechnology reports Q1 EPS (30c), consensus (37c)
- PDSB Upcoming Earnings Report: What to Expect?
- PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer